Regulation of major histocompatibility complex class II gene expression, genetic variation and disease

Genes and Immunity

Volumn 11, Issue 2, 2010, Pages 99-112

  Handunnetthi, L ^a,b   Ramagopalan, S V ^a,b   Ebers, G C ^a,b   Knight, J C ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Autoimmune; Gene regulation; HLA; MHC; Polymorphism; Transcription

Indexed keywords

CYTOKINE; HLA ANTIGEN CLASS 2; UNTRANSLATED RNA; VITAMIN D;

ALLELE; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; AUTOIMMUNE DISEASE; CHROMOSOME 6P; DENDRITIC CELL; DISEASE COURSE; DISEASE PREDISPOSITION; DNA METHYLATION; DNA SEQUENCE; ENHANCER REGION; ENVIRONMENTAL FACTOR; EPIGENETICS; GENE CONTROL; GENE DUPLICATION; GENE EXPRESSION REGULATION; GENE INTERACTION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC CONSERVATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC TRAIT; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOGENESIS; INFLAMMATORY DISEASE; MICROSATELLITE MARKER; MOLECULAR INTERACTION; NONHUMAN; NUCLEIC ACID BASE SUBSTITUTION; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; REGULATORY MECHANISM; REVIEW; T LYMPHOCYTE; TRANSCRIPTION REGULATION;

ANIMALS; COMMUNICABLE DISEASES; GENE EXPRESSION; GENETIC VARIATION; HISTOCOMPATIBILITY ANTIGENS CLASS II; REGULATORY SEQUENCES, NUCLEIC ACID;

EID: 77649340368     PISSN: 14664879     EISSN: 14765470     Source Type: Journal    
DOI: 10.1038/gene.2009.83     Document Type: Review

References (195)

1. Watts C. The exogenous pathway for antigen presentation on major histocompatibility complex class II and CD1 molecules. Nat Immunol 2004; 5: 685-692.
2. Kyewski B, Klein L. A central role for central tolerance. Annu Rev Immunol 2006; 24: 571-606.
3. Winchester R, Ebers G, Fu SM, Espinosa L, Zabriskie J, Kunkel HG. B-cell alloantigen Ag 7a in multiple sclerosis. Lancet 1975; 2: 814.
4. Jersild C, Svejgaard A, Fog T. HL-A antigens and multiple sclerosis. Lancet 1972; 1: 1240-1241.
5. 00 diabetes mellitus. Br Med J 1975; 3: 133-135.
6. Nerup J, Platz P, Andersen OO, Christy M, Lyngsoe J, Poulsen JE et al. HL-A antigens and diabetes mellitus. Lancet 1974; 2: 864-866.
7. Falchuk ZM, Rogentine GN, Strober W. Predominance of histocompatibility antigen HL-A8 in patients with gluten-sensitive enteropathy. J Clin Invest 1972; 51: 1602-1605.
8. Stokes PL, Asquith P, Holmes GK, Mackintosh P, Cooke WT. Histocompatibility antigens associated with adult coeliac disease. Lancet 1972; 2: 162-164.
9. Kagnoff MF. Celiac disease: pathogenesis of a model immunogenetic disease. J Clin Invest 2007; 117: 41-49.
10. Todd JA, Bell JI, McDevitt HO. HLA-DQ beta gene contributes to susceptibility and resistance to insulin-dependent diabetes mellitus. Nature 1987; 329: 599-604.
11. WTCCC. Genome-wide association study of 14,000 cases of seven common diseases and 3000 shared controls. Nature 2007; 447: 661-678.
12. Gregersen PK, Behrens TW. Genetics of autoimmune diseases\disorders of immune homeostasis. Nat Rev Genet 2006; 7: 917-928.
13. de Bakker PI, McVean G, Sabeti PC, Miretti MM, Green T, Marchini J et al. A high-resolution HLA and SNP haplotype map for disease association studies in the extended human MHC. Nat Genet 2006; 38: 1166-1172.
14. Vandiedonck C, Knight JC. The human major histocompat-ibility complex as a paradigm in genomics research. Brief Funct Genomic Proteomic 2009; 8: 379-394.
15. Knight JC. Human Genetic Diversity. Functional Consequences for Health and Disease, 1st edn. Oxford University Press: Oxford, 2009.
16. Jones EY, Fugger L, Strominger JL, Siebold C. MHC class II proteins and disease: a structural perspective. Nat Rev Immunol 2006; 6: 271-282.
17. Ramagopalan SV, McMahon R, Dyment DA, Sadovnick AD, Ebers GC, Wittkowski KM. An extension to a statistical approach for family based association studies provides insights into genetic risk factors for multiple sclerosis in the HLA-DRB1 gene. BMC Med Genet 2009; 10: 10.
18. Dixon AL, Liang L, Moffatt MF, Chen W, Heath S, Wong KC et al. A genome-wide association study of global gene expression. Nat Genet 2007; 39: 1202-1207.
19. Horton R, Wilming L, Rand V, Lovering RC, Bruford EA, Khodiyar VK et al. Gene map of the extended human MHC. Nat Rev Genet 2004; 5: 889-899.
20. Beck S, Trowsdale J. Sequence organisation of the class II region of the human MHC. Immunol Rev 1999; 167: 201-210.
21. Alfonso C, Karlsson L. Nonclassical MHC class II molecules. Annu Rev Immunol 2000; 18: 113-142.
22. Pieters J. MHC class II-restricted antigen processing and presentation. Adv Immunol 2000; 75: 159-208.
23. Reith W, LeibundGut-Landmann S, Waldburger JM. Regulation of MHC class II gene expression by the class II transactivator. Nat Rev Immunol 2005; 5: 793-806.
24. Chang CH, Hong SC, Hughes CC, Janeway Jr CA, Flavell RA. CIITA activates the expression of MHC class II genes in mouse T cells. Int Immunol 1995; 7: 1515-1518.
25. Baecher-Allan C, Wolf E, Hafler DA. MHC class II expression identifies functionally distinct human regulatory T cells. J Immunol 2006; 176: 4622-4631.
26. Manjuck J, Saha DC, Astiz M, Eales LJ, Rackow EC. Decreased response to recall antigens is associated with depressed costimulatory receptor expression in septic critically ill patients. J Lab Clin Med 2000; 135: 153-160.
27. Pachot A, Monneret G, Brion A, Venet F, Bohe J, Bienvenu J et al. Messenger RNA expression of major histocompatibility complex class II genes in whole blood from septic shock patients. Crit Care Med 2005; 33: 31-38.
28. Monneret G, Lepape A, Voirin N, Bohe J, Venet F, Debard AL et al. Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock. Intensive Care Med 2006; 32: 1175-1183.
29. Rimsza LM, Roberts RA, Miller TP, Unger JM, LeBlanc M, Braziel RM et al. Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. Blood 2004; 103: 4251-4258.
30. Mach B, Steimle V, Martinez-Soria E, Reith W. Regulation of MHC class II genes: lessons from a disease. Annu Rev Immunol 1996; 14: 301-331.
31. Reith W, Mach B. The bare lymphocyte syndrome and the regulation of MHC expression. Annu Rev Immunol 2001; 19: 331-373.
32. Boss JM, Jensen PE. Transcriptional regulation of the MHC class II antigen presentation pathway. Curr Opin Immunol 2003; 15: 105-111.
33. Harton JA, Ting JP. Class II transactivator: mastering the art of major histocompatibility complex expression. Mol Cell Biol 2000; 20: 6185-6194.
34. Accolla RS, Jotterand-Bellomo M, Scarpellino L, Maffei A, Carra G, Guardiola J. aIr-1, a newly found locus on mouse chromosome 16 encoding a trans-acting activator factor for MHC class II gene expression. J Exp Med 1986; 164: 369-374.
35. Steimle V, Durand B, Barras E, Zufferey M, Hadam MR, Mach B et al. A novel DNA-binding regulatory factor is mutated in primary MHC class II deficiency (bare lymphocyte syndrome). Genes Dev 1995; 9: 1021-1032.
36. Durand B, Sperisen P, Emery P, Barras E, Zufferey M, Mach B et al. RFXAP, a novel subunit of the RFX DNA binding complex is mutated in MHC class II| deficiency. EMBO J 1997; 16: 1045-1055.
37. Masternak K, Barras E, Zufferey M, Conrad B, Corthals G, Aebersold R et al. A gene encoding a novel RFX-associated transactivator is mutated in the majority of MHC class II deficiency patients. Nat Genet 1998; 20: 273-277.
38. Steimle V, Otten LA, Zufferey M, Mach B. Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome). Cell 1993; 75: 135-146.
39. Briggs L, Laird K, Boss JM, Garvie CW. Formation of the RFX gene regulatory complex induces folding of the interaction domain of RFXAP. Proteins 2009; 76: 655-664.
40. Moreno CS, Beresford GW, Louis-Plence P, Morris AC, Boss JM. CREB regulates MHC class II expression in a CIITA-dependent manner. Immunity 1999; 10: 143-151.
41. Mantovani R, Pessara U, Tronche F, Li XY, Knapp AM, Pasquali JL et al. Monoclonal antibodies to NF-Y define its function in MHC class II and albumin gene transcription. EMBO J 1992; 11: 3315-3322.
42. Seguin-Estevez Q, De Palma R, Krawczyk M, Leimgruber E, Villard J, Picard C et al. The transcription factor RFX protects MHC class II genes against epigenetic silencing by DNA methylation. J Immunol 2009; 183: 2545-2553.
43. Ting JP, Trowsdale J. Genetic control of MHC class II expression. Cell 2002; 109: S21-S33.
44. Muhlethaler-Mottet A, Krawczyk M, Masternak K, Spiliana-kis C, Kretsovali A, Papamatheakis J et al. The S box of major histocompatibility complex class II promoters is a key determinant for recruitment of the transcriptional co-activator CIITA. J Biol Chem 2004; 279: 40529-40535.
45. Muhlethaler-Mottet A, Otten LA, Steimle V, Mach B. Expression of MHC class II molecules in different cellular and functional compartments is controlled by differential usage of multiple promoters of the transactivator CIITA. EMBO J 1997; 16: 2851-2860.
46. Hakonarson H, Grant SF, Bradfield JP, Marchand L, Kim CE, Glessner JT et al. A genome-wide association study identifies KIAA0350 as a type 1 diabetes gene. Nature 2007; 448: 591-594. (Pubitemid 47206935)
47. Todd JA, Walker NM, Cooper JD, Smyth DJ, Downes K, Plagnol V et al. Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat Genet 2007; 39: 857-864.
48. Swanberg M, Lidman O, Padyukov L, Eriksson P, Akesson E, Jagodic M et al. MHC2TA is associated with differential MHC molecule expression and susceptibility to rheumatoid arthritis, multiple sclerosis and myocardial infarction. Nat Genet 2005; 37: 486-494.
49. Akkad DA, Jagiello P, Szyld P, Goedde R, Wieczorek S, Gross WL et al. Promoter polymorphism rs3087456 in the MHC class II transactivator gene is not associated with susceptibility for selected autoimmune diseases in German patient groups. Int J Immunogenet 2006; 33: 59-61.
50. Eyre S, Bowes J, Spreckley K, Potter C, Ring S, Strachan D et al. Investigation of the MHC2TA gene, associated with rheumatoid arthritis in a Swedish population, in a UK rheumatoid arthritis cohort. Arthritis Rheum 2006; 54: 3417-3422.
51. Harrison P, Pointon JJ, Farrar C, Harin A, Wordsworth BP. MHC2TA promoter polymorphism (-168*G/A, rs3087456) is not associated with susceptibility to rheumatoid arthritis in British Caucasian rheumatoid arthritis patients. Rheumatology (Oxford) 2007; 46: 409-411.
52. Olsson T, Jagodic M, Piehl F, Wallstrom E. Genetics of autoimmune neuroinflammation. Curr Opin Immunol 2006; 18: 643-649.
53. Bronson PG, Criswell LA, Barcellos LF. The MHC2TA-168A/ G polymorphism and risk for rheumatoid arthritis: a meta-analysis of 6861 patients and 9270 controls reveals no evidence for association. Ann Rheum Dis 2008; 67: 933-936.
54. Dorn A, Fehling HJ, Koch W, Le Meur M, Gerlinger P, Benoist C et al. B-cell control region at the 5 end of a major histocompatibility complex class II gene: sequences and factors. Mol Cell Biol 1988; 8: 3975-3987.
55. Carson S, Wiles MV. Far upstream regions of class II MHC Ea are necessary for position-independent, copy-dependent expression of Ea transgene. Nucleic Acids Res 1993; 21: 2065-2072.
56. van Ewijk W, Ron Y, Monaco J, Kappler J, Marrack P, Le Meur M et al. Compartmentalization of MHC class II| gene expression in transgenic mice. Cell 1988; 53: 357-370.
57. Feriotto G, Mischiati C, Bianchi N, Rutigliano C, Giacomini P, Gambari R. Sequencing of an upstream region of the human HLA-DRA gene containing X and Y boxes. Nucleic Acids Res 1995; 23: 1671-1678.
58. Masternak K, Peyraud N, Krawczyk M, Barras E, Reith W. Chromatin remodeling and extragenic transcription at the MHC class II locus control region. Nat Immunol 2003; 4: 132-137.
59. Krawczyk M, Peyraud N, Rybtsova N, Masternak K, Bucher P, Barras E et al. Long distance control of MHC class II expression by multiple distal enhancers regulated by regulatory factor X complex and CIITA. J Immunol 2004; 173: 6200-6210.
60. Gomez JA, Majumder P, Nagarajan UM, Boss JM. X box-like sequences in the MHC class II region maintain regulatory function. J Immunol 2005; 175: 1030-1040.
61. von Salome J, Gyllensten U, Bergstrom TF. Full-length sequence analysis of the HLA-DRB1 locus suggests a recent origin of alleles. Immunogenetics 2007; 59: 261-271.
62. Andersson G. Evolution of the human HLA-DR region. Front Biosci 1998; 3: d739-d745.
63. Trowsdale J. 'Both man & bird & beast' comparative organization of MHC genes. Immunogenetics 1995; 41: 1-17.
64. Hughes AL, Nei M. Nucleotide substitution at major histocompatibility complex class II loci: evidence for over-dominant selection. Proc Natl Acad Sci USA 1989; 86: 958-962.
65. Loisel DA, Rockman MV, Wray GA, Altmann J, Alberts SC. Ancient polymorphism and functional variation in the primate MHC-DQA1 5 cis-regulatory region. Proc Natl Acad Sci USA 2006; 103: 16331-16336.
66. Liu X, Fu Y, Liu Z, Lin B, Xie Y, Liu Y et al. An ancient balanced polymorphism in a regulatory region of human major histocompatibility complex is retained in Chinese minorities but lost worldwide. Am J Hum Genet 2006; 78: 393-400.
67. Leen MP, Ogutu ER, Gorski J. Structural and functional analysis of HLA-DR beta-promoter polymorphism and isomorphism. Hum Immunol 1994; 41: 112-120.
68. Perfetto C, Zacheis M, McDaid D, Meador III JW, Schwartz BD. Polymorphism in the promoter region of HLA-DRB genes. Hum Immunol 1993; 36: 27-33.
69. Singal DP, Qiu X, D'Souza M, Sood SK. Polymorphism in the upstream regulatory regions of HLA-DRB genes. Immuno-genetics 1993; 37: 143-147.
70. Louis P, Eliaou JF, Kerlan-Candon S, Pinet V, Vincent R, Clot J. Polymorphism in the regulatory region of HLA-DRB genes correlating with haplotype evolution. Immunogenetics 1993; 38: 21-26.
71. Singal DP, D'Souza M, Sood SK, Qiu X. Sequence-specific interactions of the nuclear proteins with polymorphic upstream regulatory regions of HLA-DRB genes. Transplant Proc 1993; 25: 180-182.
72. Emery P, Mach B, Reith W. The different level of expression of HLA-DRB1 and-DRB3 genes is controlled by conserved isotypic differences in promoter sequence. Hum Immunol 1993; 38: 137-147.
73. Louis P, Vincent R, Cavadore P, Clot J, Eliaou JF. Differential transcriptional activities of HLA-DR genes in the various haplotypes. J Immunol 1994; 153: 5059-5067.
74. Singal DP, Qiu X. Polymorphism in both X and Y box motifs controls level of expression of HLA-DRB1 genes. Immunoge-netics 1996; 43: 50-56. (Pubitemid 126437398)
75. Sindwani S, Singal DP. Polymorphism in the Y box controls level of cytokine-mediated expression of HLA-DRB1 genes. Tissue Antigens 2001; 58: 315-323. (Pubitemid 34095140)
76. Louis P, Pinet V, Cavadore P, Kerlan-Candon S, Clot J, Eliaou JF. Differential expression of HLA-DRB genes according to the polymorphism of their regulatory region. C R Acad Sci III 1994; 317: 161-166.
77. Vincent R, Louis-Plence P, Gaillard F, Clot J, Eliaou JF. Qualitative and quantitative analysis of HLA-DRB gene expression. J Rheumatol 1997; 24: 225-226.
78. Singal DP, Qiu X. Polymorphism in the upstream regulatory region and level of expression of HLA-DRB genes. Mol Immunol 1994; 31: 1117-1120.
79. Vincent R, Louis P, Gongora C, Papa I, Clot J, Eliaou JF. Quantitative analysis of the expression of the HLA-DRB genes at the transcriptional level by competitive polymerase chain reaction. J Immunol 1996; 156: 603-610.
80. Kerlan-Candon S, Combe B, Vincent R, Clot J, Pinet V, Eliaou JF. HLA-DRB1 gene transcripts in rheumatoid arthritis. Clin Exp Immunol 2001; 124: 142-149.
81. Leen MP, Gorski J. Differential expression of isomorphic HLA-DR beta genes is not a sole function of transcription. Hum Immunol 1996; 50: 111-120.
82. Janitz M, Mitchison A, Reiners-Schramm L, Lauster R. Polymorphic MHC class II promoters exhibit distinct expression pattern in various antigen-presenting cell lines. Tissue Antigens 1997; 49: 99-106.
83. Baumgart M, Moos V, Schuhbauer D, Muller B. Differential expression of major histocompatibility complex class II genes on murine macrophages associated with T cell cytokine profile and protective/suppressive effects. Proc Natl Acad Sci USA 1998; 95: 6936-6940.
84. Bontrop R, Ottenhoff T, Van Miltenburg R, Elferink D, De Vries R, Giphart M. Quantitative and qualitative differences in HLA-DR molecules correlated with antigen-presentation capacity. Eur J Immunol 1986; 16: 133-138.
85. Irle C, Jaques D, Tiercy JM, Fuggle SV, Gorski J, Termijtelen A et al. Functional polymorphism of each of the two HLA-DR beta chain loci demonstrated with antigen-specific DR3-and DRw52-restricted T cell clones. J Exp Med 1988; 167: 853-872.
86. Beaty JS, Sukiennicki TL, Nepom GT. Allelic variation in transcription modulates MHC class II expression and function. Microbes Infect 1999; 1: 919-927.
87. Andersen LC, Beaty JS, Nettles JW, Seyfried CE, Nepom GT, Nepoom BS. Allelic polymorphism in transcriptional regulatory regions of HLA-DQB genes. J Exp Med 1991; 173: 181-192.
88. Ferstl B, Zacher T, Lauer B, Blagitko-Dorfs N, Carl A, Wassmuth R. Allele-specific quantification of HLA-DQB1 gene expression by real-time reverse transcriptase-polymer-ase chain reaction. Genes Immun 2004; 5: 405-416.
89. Cesari M, Caillens H, Cadet F, Pabion M. In vivo analysis of HLA-DQ gene expression in heterozygous cell lines. Immunogenetics 1999; 50: 309-318.
90. Nepom GT, Chung J, West KA. Differential expression of HLA-DQB1 alleles in a heterozygous cell line. Immunogenetics 1995; 42: 143-148.
91. Beaty JS, West KA, Nepom GT. Functional effects of a natural polymorphism in the transcriptional regulatory sequence of HLA-DQB1. Mol Cell Biol 1995; 15: 4771-4782.
92. Takase H, Yu CR, Mahdi RM, Douek DC, Dirusso GB, Midgley FM et al. Thymic expression of peripheral tissue antigens in humans: a remarkable variability among individuals. Int Immunol 2005; 17: 1131-1140.
93. Liston A, Lesage S, Gray DH, Boyd RL, Goodnow CC. Genetic lesions in T-cell tolerance and thresholds for autoimmunity. Immunol Rev 2005; 204: 87-101.
94. Ramagopalan SV, Morris AP, Dyment DA, Herrera BM, DeLuca GC, Lincoln MR et al. The inheritance of resistance alleles in multiple sclerosis. PLoS Genet 2007; 3: 1607-1613.
95. Svejgaard A. The immunogenetics of multiple sclerosis. Immunogenetics 2008; 60: 275-286.
96. Ramagopalan SV, Knight JC, Ebers GC. Multiple sclerosis and the major histocompatibility complex. Curr Opin Neurol 2009; 22: 219-225.
97. Dyment DA, Herrera BM, Cader MZ, Willer CJ, Lincoln MR, Sadovnick AD et al. Complex interactions among MHC haplotypes in multiple sclerosis: susceptibility and resistance. Hum Mol Genet 2005; 14: 2019-2026.
98. Modin H, Olsson W, Hillert J, Masterman T. Modes of action of HLA-DR susceptibility specificities in multiple sclerosis. Am J Hum Genet 2004; 74: 1321-1322.
99. Bell GI, Horita S, Karam JH. A polymorphic locus near the human insulin gene is associated with insulin-dependent diabetes mellitus. Diabetes 1984; 33: 176-183.
100. Bennett ST, Lucassen AM, Gough SC, Powell EE, Undlien DE, Pritchard LE et al. Susceptibility to human type 1 diabetes at IDDM2 is determined by tandem repeat variation at the insulin gene minisatellite locus. Nat Genet 1995; 9: 284-292.
101. Pugliese A, Zeller M, Fernandez A, Zalcberg LJ, Bartlett RJ, Ricordi C et al. The insulin gene is transcribed in the human thymus and transcription levels correlated with allelic variation at the INS VNTR-IDDM2 susceptibility locus for type 1 diabetes. Nat Genet 1997; 15: 293-297.
102. Vafiadis P, Bennett ST, Todd JA, Nadeau J, Grabs R, Goodyer CG et al. Insulin expression in human thymus is modulated by INS VNTR alleles at the IDDM2 locus. Nat Genet 1997; 15: 289-292.
103. Cocozza S, Riccardi G, Monticelli A, Capaldo B, Genovese S, Krogh V et al. Polymorphism at the 5 end flanking region of the insulin gene is associated with reduced insulin secretion in healthy individuals. Eur J Clin Invest 1988; 18: 582-586.
104. Lucassen AM, Screaton GR, Julier C, Elliott TJ, Lathrop M, Bell JI. Regulation of insulin gene expression by the IDDM associated, insulin locus haplotype. Hum Mol Genet 1995; 4: 501-506.
105. Zhong G, Fan T, Liu L. Chlamydia inhibits interferon gamma-inducible major histocompatibility complex class II expression by degradation of upstream stimulatory factor 1. J Exp Med 1999; 189: 1931-1938.
106. Frodsham AJ, Hill AV. Genetics of infectious diseases. Hum Mol Genet 2004; 13: R187-R194.
107. Rigby WF, Waugh M, Graziano RF. Regulation of human monocyte HLA-DR and CD4 antigen expression, and antigen presentation by 1,25-dihydroxyvitamin D3. Blood 1990; 76: 189-197.
108. Vieth R, Cole DE, Hawker GA, Trang HM, Rubin LA. Wintertime vitamin D insufficiency is common in young Canadian women, and their vitamin D intake does not prevent it. Eur J Clin Nutr 2001; 55: 1091-1097.
109. Kimlin MG. Geographic location and vitamin D synthesis. Mol Aspects Med 2008; 29: 453-461.
110. Kurtzke JF. A reassessment of the distribution of multiple sclerosis. Part one. Acta Neurologica Scandinavica 1975; 51: 110-136.
111. van der Mei IA, Ponsonby AL, Blizzard L, Dwyer T. Regional variation in multiple sclerosis prevalence in Australia and its association with ambient ultraviolet radiation. Neuro-epidemiology 2001; 20: 168-174.
112. Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006; 296: 2832-2838. (Pubitemid 44969183)
113. Davies PD, Brown RC, Woodhead JS. Serum concentrations of vitamin D metabolites in untreated tuberculosis. Thorax 1985; 40: 187-190.
114. Wilkinson RJ, Llewelyn M, Toossi Z, Patel P, Pasvol G, Lalvani A et al. Influence of vitamin D deficiency and vitamin D receptor polymorphisms on tuberculosis among Gujarati Asians in west London: a case-control study. Lancet 2000; 355: 618-621.
115. Nagpal S, Na S, Rathnachalam R. Noncalcemic actions of vitamin D receptor ligands. Endocr Rev 2005; 26: 662-687.
116. Stone LA, Weaver VM, Bruns ME, Welsh J. Vitamin D receptors in intestine, kidney and thymus of streptozotocin diabetic rats. Diabetes Res 1990; 15: 165-172.
117. Veldman CM, Cantorna MT, DeLuca HF. Expression of 1,25-dihydroxyvitamin D(3) receptor in the immune system. Arch Biochem Biophys 2000; 374: 334-338.
118. Ramagopalan SV, Maugeri NJ, Handunnetthi L, Lincoln MR, Orton SM, Dyment DA et al. Expression of the multiple sclerosis-associated MHC class II allele HLA-DRB1*1501 is regulated by vitamin D. PLoS Genet 2009; 5: e1000369.
119. Bornman L, Campbell SJ, Fielding K, Bah B, Sillah J, Gustafson P et al. Vitamin D receptor polymorphisms and susceptibility to tuberculosis in West Africa: a case-control and family study. J Infect Dis 2004; 190: 1631-1641.
120. Chocano-Bedoya P, Ronnenberg AG. Vitamin D and tuberculosis. Nutr Rev 2009; 67: 289-293.
121. Adamski J, Ma Z, Nozell S, Benveniste EN. 17beta-estradiol inhibits class II major histocompatibility complex (MHC) expression: influence on histone modifications and cbp recruitment to the class II MHC promoter. Mol Endocrinol 2004; 18: 1963-1974.
122. Ramagopalan SV, Valdar W, Criscuoli M, DeLuca GC, Dyment DA, Orton SM et al. Age of puberty and the risk of multiple sclerosis: a population based study. Eur J Neurol 2009; 16: 342-347.
123. Whitacre CC. Sex differences in autoimmune disease. Nat Immunol 2001; 2: 777-780.
124. Sutherland H, Bickmore WA. Transcription factories: gene expression in unions? Nat Rev Genet 2009; 10: 457-466.
125. Fraser P, Bickmore W. Nuclear organization of the genome and the potential for gene regulation. Nature 2007; 447: 413-417.
126. Phillips JE, Corces VG. CTCF: master weaver of the genome. Cell 2009; 137: 1194-1211.
127. Gaszner M, Felsenfeld G. Insulators: exploiting transcriptional and epigenetic mechanisms. Nat Rev Genet 2006; 7: 703-713.
128. Burgess-Beusse B, Farrell C, Gaszner M, Litt M, Mutskov V, Recillas-Targa F et al. The insulation of genes from external enhancers and silencing chromatin. Proc Natl Acad Sci USA 2002; 99: 16433-16437.
129. Han L, Lee DH, Szabo PE. CTCF is the master organizer of domain-wide allele-specific chromatin at the H19/Igf2 imprinted region. Mol Cell Biol 2008; 28: 1124-1135.
130. Ling JQ, Li T, Hu JF, Vu TH, Chen HL, Qiu XW et al. CTCF mediates interchromosomal colocalization between Igf2/H19 and Wsb1/Nf1. Science 2006; 312: 269-272.
131. Bell AC, Felsenfeld G. Methylation of a CTCF-dependent boundary controls imprinted expression of the Igf2 gene. Nature 2000; 405: 482-485.
132. Hark AT, Schoenherr CJ, Katz DJ, Ingram RS, Levorse JM, Tilghman SM. CTCF mediates methylation-sensitive enhancer-blocking activity at the H19/Igf2 locus. Nature 2000; 405: 486-489.
133. Majumder P, Gomez JA, Boss JM. The human major histocompatibility complex class II HLA-DRB1 and HLA-DQA1 genes are separated by a CTCF-binding enhancer-blocking element. J Biol Chem 2006; 281: 18435-18443.
134. Majumder P, Gomez JA, Chadwick BP, Boss JM. The insulator factor CTCF controls MHC class II gene expression and is required for the formation of long-distance chromatin interactions. J Exp Med 2008; 205: 785-798.
135. Smith ME, Holgate CS, Williamson JM, Grigor I, Quirke P, Bird CC. Major histocompatibility complex class II antigen expression in B and T cell non-Hodgkins lymphoma. J Clin Pathol 1987; 40: 34-41.
136. Cuddapah S, Jothi R, Schones DE, Roh TY, Cui K, Zhao K. Global analysis of the insulator binding protein CTCF in chromatin barrier regions reveals demarcation of active and repressive domains. Genome Res 2009; 19: 24-32.
137. Kim TH, Abdullaev ZK, Smith AD, Ching KA, Loukinov DI, Green RD et al. Analysis of the vertebrate insulator protein CTCF-binding sites in the human genome. Cell 2007; 128: 1231-1245.
138. Barski A, Cuddapah S, Cui K, Roh TY, Schones DE, Wang Z et al. High-resolution profiling of histone methylations in the human genome. Cell 2007; 129: 823-837.
139. Kurokawa R, Rosenfeld MG, Glass CK. Transcriptional regulation through noncoding RNAs and epigenetic modifications. RNA Biol 2009; 6: 233-236.
140. Suzuki MM, Bird A. DNA methylation landscapes: provocative insights from epigenomics. Nat Rev Genet 2008; 9: 465-476.
141. Schones DE, Zhao K. Genome-wide approaches to studying chromatin modifications. Nat Rev Genet 2008; 9: 179-191.
142. Wang SC, Oelze B, Schumacher A. Age-specific epigenetic drift in late-onset Alzheimers disease. PLoS ONE 2008; 3: e2698.
143. Liu L, Li Y, Tollefsbol TO. Gene-environment interactions and epigenetic basis of human diseases. Curr Issues Mol Biol 2008; 10: 25-36.
144. Jirtle RL, Skinner MK. Environmental epigenomics and disease susceptibility. Nat Rev Genet 2007; 8: 253-262.
145. Rakyan VK, Hildmann T, Novik KL, Lewin J, Tost J, Cox AV et al. DNA methylation profiling of the human major histocompatibility complex: a pilot study for the human epigenome project. PLoS Biol 2004; 2: e405.
146. Tomazou EM, Rakyan VK, Lefebvre G, Andrews R, Ellis P, Jackson DK et al. Generation of a genomic tiling array of the human major histocompatibility complex (MHC) and its application for DNA methylation analysis. BMC Med Genomics 2008; 1: 19.
147. Wright KL, Ting JP. Epigenetic regulation of MHC-II and CIITA genes. Trends Immunol 2006; 27: 405-412.
148. Zika E, Ting JP. Epigenetic control of MHC-II: interplay between CIITA and histone-modifying enzymes. Curr Opin Immunol 2005; 17: 58-64.
149. Tzortzakaki E, Spilianakis C, Zika E, Kretsovali A, Papa-matheakis J. Steroid receptor coactivator 1 links the steroid and interferon gamma response pathways. Mol Endocrinol 2003; 17: 2509-2518.
150. Beresford GW, Boss JM. CIITA coordinates multiple histone acetylation modifications at the HLA-DRA promoter. Nat Immunol 2001; 2: 652-657.
151. Pai RK, Convery M, Hamilton TA, Boom WH, Harding CV. Inhibition of IFN-gamma-induced class II transactivator expression by a 19-kDa lipoprotein from Mycobacterium tuberculosis: a potential mechanism for immune evasion. J Immunol 2003; 171: 175-184.
152. Pennini ME, Pai RK, Schultz DC, Boom WH, Harding CV. Mycobacterium tuberculosis 19-kDa lipoprotein inhibits IFN-gamma-induced chromatin remodeling of MHC2TA by TLR2 and MAPK signaling. J Immunol 2006; 176: 4323-4330.
153. Ben-Dov C, Hartmann B, Lundgren J, Valcarcel J. Genome-wide analysis of alternative pre-mRNA splicing. J Biol Chem 2008; 283: 1229-1233.
154. Blencowe BJ. Alternative splicing: new insights from global analyses. Cell 2006; 126: 37-47.
155. Kralovicova J, Houngninou-Molango S, Kramer A, Vore-chovsky I. Branch site haplotypes that control alternative splicing. Hum Mol Genet 2004; 13: 3189-3202.
156. Horton R, Gibson R, Coggill P, Miretti M, Allcock RJ, Almeida J et al. Variation analysis and gene annotation of eight MHC haplotypes: the MHC haplotype project. Immunogenetics 2008; 60: 1-18.
157. Wang GS, Cooper TA. Splicing in disease: disruption of the splicing code and the decoding machinery. Nat Rev Genet 2007; 8: 749-761.
158. Valentonyte R, Hampe J, Huse K, Rosenstiel P, Albrecht M, Stenzel A et al. Sarcoidosis is associated with a truncating splice site mutation in BTNL2. Nat Genet 2005; 37: 357-364.
159. Nguyen T, Liu XK, Zhang Y, Dong C. BTNL2, a butyrophilin-like molecule that functions to inhibit T cell activation. J Immunol 2006; 176: 7354-7360.
160. Boyd SD. Everything you wanted to know about small RNA but were afraid to ask. Lab Invest 2008; 88: 569-578.
161. Johnston RJ, Hobert O. A microRNA controlling left/right neuronal asymmetry in Caenorhabditis elegans. Nature 2003; 426: 845-849.
162. Chen CZ, Li L, Lodish HF, Bartel DP. MicroRNAs modulate hematopoietic lineage differentiation. Science 2004; 303: 83-86.
163. Lecellier CH, Dunoyer P, Arar K, Lehmann-Che J, Eyquem S, Himber C et al. A cellular microRNA mediates antiviral defense in human cells. Science 2005; 308: 557-560.
164. Tan Z, Randall G, Fan J, Camoretti-Mercado B, Brockman-Schneider R, Pan L et al. Allele-specific targeting of microRNAs to HLA-G and risk of asthma. Am J Hum Genet 2007; 81: 829-834.
165. Shin JS, Ebersold M, Pypaert M, Delamarre L, Hartley A, Mellman I. Surface expression of MHC class II in dendritic cells is controlled by regulated ubiquitination. Nature 2006; 444: 115-118.
166. Iafrate AJ, Feuk L, Rivera MN, Listewnik ML, Donahoe PK, Qi Y et al. Detection of large-scale variation in the human genome. Nat Genet 2004; 36: 949-951.
167. Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res 2001; 29: 308-311.
168. Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, Zahler AM et al. The human genome browser at UCSC. Genome Res 2002; 12: 996-1006.
169. van Belzen MJ, Koeleman BP, Crusius JB, Meijer JW, Bardoel AF, Pearson PL et al. Defining the contribution of the HLA region to cis DQ2-positive coeliac disease patients. Genes Immun 2004; 5: 215-220.
170. Stokkers PC, Reitsma PH, Tytgat GN, van Deventer SJ. HLA-DR and-DQ phenotypes in inflammatory bowel disease: a meta-analysis. Gut 1999; 45: 395-401.
171. Ahmad T, Armuzzi A, Bunce M, Mulcahy-Hawes K, Marshall SE, Orchard TR et al. The molecular classification of the clinical manifestations of Crohns disease. Gastroenter-ology 2002; 122: 854-866.
172. Newman B, Silverberg MS, Gu X, Zhang Q, Lazaro A, Steinhart AH et al. CARD15 and HLA DRB1 alleles influence susceptibility and disease localization in Crohn s disease. Am J Gastroenterol 2004; 99: 306-315.
173. Ahmad T, Marshall SE, Jewell D. Genetics of inflammatory bowel disease: the role of the HLA complex. World J Gastroenterol 2006; 12: 3628-3635.
174. Ahmad T, Armuzzi A, Neville M, Bunce M, Ling KL, Welsh KI et al. The contribution of human leucocyte antigen complex genes to disease phenotype in ulcerative colitis. Tissue Antigens 2003; 62: 527-535.
175. Fernando MM, Stevens CR, Walsh EC, De Jager PL, Goyette P, Plenge RM et al. Defining the role of the MHC in autoimmuni-ty: a review and pooled analysis. PLoS Genet 2008; 4: e1000024.
176. Heward JM, Allahabadia A, Daykin J, Carr-Smith J, Daly A, Armitage M et al. Linkage disequilibrium between the human leukocyte antigen class II region of the major histocompatibility complex and Graves disease: replication using a population case control and family-based study. J Clin Endocrinol Metab 1998; 83: 3394-3397.
177. Simmonds MJ, Howson JM, Heward JM, Cordell HJ, Foxall H, Carr-Smith J et al. Regression mapping of association between the human leukocyte antigen region and Graves disease. Am J Hum Genet 2005; 76: 157-163.
178. Zeitlin AA, Heward JM, Newby PR, Carr-Smith JD, Franklyn JA, Gough SC et al. Analysis of HLA class II genes in Hashimotos thyroiditis reveals differences compared to Graves disease. Genes Immun 2008; 9: 358-363.
179. Lincoln MR, Ramagopalan SV, Chao MJ, Herrera BM, Deluca GC, Orton SM et al. Epistasis among HLA-DRB1, HLA-DQA1, and HLA-DQB1 loci determines multiple sclerosis susceptibility. Proc Natl Acad Sci USA 2009; 106: 7542-7547.
180. Matsuki K, Grumet FC, Lin X, Gelb M, Guilleminault C, Dement WC et al. DQ (rather than DR) gene marks susceptibility to narcolepsy. Lancet 1992; 339: 1052.
181. Juji T, Satake M, Honda Y, Doi Y. HLA antigens in Japanese patients with narcolepsy. All the patients were DR2 positive. Tissue Antigens 1984; 24: 316-319.
182. Mignot E, Lin X, Arrigoni J, Macaubas C, Olive F, Hallmayer J et al. DQB1*0602 and DQA1*0102 (DQ1) are better markers than DR2 for narcolepsy in Caucasian and black Americans. Sleep 1994; 17: S60-S67.
183. Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 1987; 30: 1205-1213.
184. Graham RR, Ortmann WA, Langefeld CD, Jawaheer D, Selby SA, Rodine PR et al. Visualizing human leukocyte antigen class II risk haplotypes in human systemic lupus erythema-tosus. Am J Hum Genet 2002; 71: 543-553.
185. Tsao BP. Update on human systemic lupus erythematosus genetics. Curr Opin Rheumatol 2004; 16: 513-521.
186. Kawabata Y, Ikegami H, Kawaguchi Y, Fujisawa T, Shintani M, Ono M et al. Asian-specific HLA haplotypes reveal heterogeneity of the contribution of HLA-DR and-DQ haplotypes to susceptibility to type 1 diabetes. Diabetes 2002; 51: 545-551.
187. She JX. Susceptibility to type I diabetes: HLA-DQ and DR revisited. Immunol Today 1996; 17: 323-329.
188. Lambert AP, Gillespie KM, Thomson G, Cordell HJ, Todd JA, Gale EA et al. Absolute risk of childhood-onset type 1 diabetes defined by human leukocyte antigen class II genotype: a population-based study in the United Kingdom. J Clin Endocrinol Metab 2004; 89: 4037-4043.
189. Erlich HA, Bugawan TL, Scharf S, Nepom GT, Tait B, Griffith RL. HLA-DQ beta sequence polymorphism and genetic susceptibility to IDDM. Diabetes 1990; 39: 96-103.
190. Almarri A, Batchelor JR. HLA and hepatitis B infection. Lancet 1994; 344: 1194-1195.
191. Kamatani Y, Wattanapokayakit S, Ochi H, Kawaguchi T, Takahashi A, Hosono N et al. A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians. Nat Genet 2009; 41: 591-595.
192. Anderson DC, van Schooten WC, Barry ME, Janson AA, Buchanan TM, de Vries RR. A Mycobacterium leprae-specific human T cell epitope cross-reactive with an HLA-DR2 peptide. Science 1988; 242: 259-261.
193. Vanderborght PR, Pacheco AG, Moraes ME, Antoni G, Romero M, Verville A et al. HLA-DRB1*04 and DRB1*10 are associated with resistance and susceptibility, respectively, in Brazilian and Vietnamese leprosy patients. Genes Immun 2007; 8: 320-324.
194. Ravikumar M, Dheenadhayalan V, Rajaram K, Lakshmi SS, Kumaran PP, Paramasivan CN et al. Associations of HLA-DRB1, DQB1 and DPB1 alleles with pulmonary tuberculosis in south India. Tuber Lung Dis 1999; 79: 309-317.
195. Singh SP, Mehra NK, Dingley HB, Pande JN, Vaidya MC. Human leukocyte antigen (HLA)-linked control of susceptibility to pulmonary tuberculosis and association with HLA-DR types. J Infect Dis 1983; 148: 676-681.